Sanofi

Stéphane Illiano

Andreas Evers

Elisabetta Bianchi

Olivier Duclos

Sergio Mallart

Frank Marguet

Nis Halland

Raffaele Ingenito

Alessia Santoprete

Paola Magotti

Claire Minoletti-Hochepied

Jean-Michel Altenburger

Valérie Fossey

Philip Janiak

Ralf Elvert

Géraldine Manette

Denis Brasseur

Philippe Beauverger

Ziyu Li

Marie-Laure Ozoux

Daniela Roversi

Laetitia Ledein

Laurence Lucats

Martina Tripepi

A biologically active single chain Relaxin peptide having the formula N-Ac-L-E-G-R-E-K-V-R-A-X-I-X-X-E-G-X-S-T-F-S-X-R-A-X-NH-C, or a salt of solvate thereof, is described.

Modified lipidated relaxin B chain peptides and their therapeutic use

Provided is a biologically active single chain Relaxin peptide having the following formula (I):N-Ac-(E)-X-E-G-R-E-X-V-R-X-X-I-X-X-E-G-X-S-X-X-X-X-R-(X)-(X)-(K)-(X)-(gE)-X-C; or a salt or solvate thereof. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, and the peptide or the pharmaceutical composition for its use as a medicament.

Modified lipidated Relaxin B chain peptides and their therapeutic use

Provided is a biologically active single chain Relaxin peptide having the following formula (I): N-X-(E)-X-E-G-R-E-X-V-R-X-X-I-X-X-E-G-X-S-X-X-X-X-R-(X)-(X)-(X)-NH-C. Also provided is a pharmaceutical composition comprising at least one peptide of the invention, or a pharmaceutically acceptable salt or a solvate thereof. Further provided is the peptide, a pharmaceutically acceptable salt or solvate thereof, or the pharmaceutical composition for use as a medicament.

Modified relaxin B chain peptides and their therapeutic use

Provided is a biologically active single chain Relaxin peptide having the following formula (I) (SEQ ID NO 105): N-Ac-X-E-G-R-E-X-V-R-X-X-I-X-X-E-G-X-S-X-X-X-X-X-X-X-NH-Cor a salt or solvate thereof. Also provided is a pharmaceutical composition comprising at least one biologically active single chain Relaxin peptide. Uses of the peptide or the pharmaceutical composition as a medicament are also provided.

The invention relates to compounds corresponding to formula (I), in the form of the base or of an acid-addition salt: in which n is equal to 0, 1, 2, 3 or 4; m is equal to 0, 1 or 2; o is equal to 0 or 1; X represents a group &#x2014;CH, &#x2014;CH(R')&#x2014;, &#x2014;NH(R&#x2032;)&#x2014; or a heteroatom chosen from O and S, it being understood that R&#x2032; represents a group &#x2014;(C1-C5)alkyl, &#x2014;(C1-C5)alkoxy, &#x2014;CH-aryl, &#x2014;C(O)R5 or &#x2014;COOR5; R1, R2, R5 are as defined in the specification.

Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof

The present invention relates to novel substituted dihydropyrazolone derivatives, to their preparation and to their therapeutic use as activators of the transcription factor HIF.

Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof as HIF activators

Growing community of inventors

Paris, France

Stéphane Illiano